Blueprint Medicines Corp
BPMC
Market Cap$8.3B
Close$
$95.39
25.7% downside
Current Fair Value
25.7% downsideOvervalued by 25.7% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $8.30 Billion |
|---|---|
| Enterprise Value | $8.30 Billion |
| Dividend Yield | $0 (0%) |
| Earnings per Share | $-1.07 |
| Beta | 0.83 |
| Outstanding Shares | 63,600,000 |
Return
| Return on Equity | - |
|---|---|
| Return on Assets | - |
| Return on Invested Capital | - |
Valuation & Multiples
| P/E Ratio | -52.42 |
|---|---|
| PEG | 52.71 |
| Price to Sales | 16.04 |
| Price to Book Ratio | 25.67 |
| Enterprise Value to Revenue | 14.77 |
| Enterprise Value to EBIT | -70.22 |
| Enterprise Value to Net Income | -54 |
| Total Debt to Enterprise | 0.02 |
| Debt to Equity | 0.37 |
Revenue Sources
No data
Insider Trades
ESG Score
No data
About Blueprint Medicines Corp
CEO: Jeffrey Albers